Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
Crossref DOI link: https://doi.org/10.1007/s13300-019-0627-1
Published Online: 2019-05-10
Published Print: 2019-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Vetter, Marion L.
Johnsson, Kristina
Hardy, Elise
Wang, Hui
Iqbal, Nayyar
Funding for this research was provided by:
Bristol-Myers Squibb
AstraZeneca
Article History
Received: 18 January 2019
First Online: 10 May 2019